确认！赛诺菲降脂药波立达拟退出中国市场

Core Viewpoint - Sanofi is rapidly filling its cardiovascular product pipeline through acquisitions while planning to exit the Chinese market for its cholesterol-lowering drug, Praluent (alirocumab) due to increased competition from domestic PCSK9 inhibitors and supply challenges [1][2][4]. Group 1: Market Strategy - Sanofi is optimizing its cardiovascular market strategy by discontinuing the promotion of Praluent in China, which is influenced by the inclusion of more domestic PCSK9 inhibitors in the National Medical Insurance Drug List by 2025 [1][2]. - The company confirmed the exit of Praluent from the Chinese market, citing both competitive and supply chain challenges [1][4]. Group 2: Product Pipeline - Sanofi has acquired rights to develop and commercialize the investigational drug, Patisiran sodium injection, in Greater China, which targets conditions like familial chylomicronemia syndrome and severe hypertriglyceridemia [5]. - Earlier, Sanofi also announced the acquisition of exclusive rights to develop and commercialize Aficamten in Greater China, a new generation selective small molecule cardiac myosin inhibitor [5].